Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

26 total trials 3 currently recruiting 18 completed

Trial Pipeline

RECRUITING

Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry

NCT06974981

RECRUITING NA

Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

NCT03184038

RECRUITING NA

High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery

NCT02757859

ACTIVE NOT RECRUITING Phase 2

Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer

NCT03796884

ACTIVE NOT RECRUITING Phase 2

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

NCT03198026

ACTIVE NOT RECRUITING NA

Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma

NCT03251027

ACTIVE NOT RECRUITING Phase 2

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

NCT02068586

ACTIVE NOT RECRUITING Phase 1

High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

NCT01655836

COMPLETED Phase 1

Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

NCT03472573

COMPLETED NA

Decision Counseling Program in Increasing Shared Decision Making and Clinical Trial Participation in Patients With Stage 0-IV Lung Cancer (Free to Breathe)

NCT03820557

COMPLETED Early Phase 1

Contrast-Enhanced Subharmonic Ultrasound Imaging in Improving Characterization of Adnexal Masses in Patients Undergoing Surgery

NCT03297112

COMPLETED Early Phase 1

Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy

NCT03039413

COMPLETED Phase 2

Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia

NCT02583893

COMPLETED Phase 1

Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas

NCT02186509

COMPLETED Phase 2

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

NCT01818063

COMPLETED Phase 1

Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer

NCT01878695

COMPLETED Phase 2

A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer

NCT01356628

COMPLETED Phase 2

Digoxin for Recurrent Prostate Cancer

NCT01162135

COMPLETED Early Phase 1

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

NCT01184885

COMPLETED Phase 1

Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases

NCT00838929

COMPLETED Early Phase 1

Fatigue and Pancreas and Bile Duct Cancer Study

NCT00902759

COMPLETED Phase 3

Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer

NCT00806611

COMPLETED Phase 1

Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients

NCT00437372

COMPLETED Phase 1

A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative

NCT00429143

COMPLETED NA

Using the Active Breathing Control Device to Reduce Radiation Side Effects to Critical Structures in Breast Cancer

NCT00328783

COMPLETED Phase 1

Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00003268

What the Pipeline for Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Shows

According to the ClinicalTrials.gov registry, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University is linked to 26 US clinical trials across every stage of research activity. Of those, 3 studies are currently recruiting — about 12% of the sponsor's indexed portfolio — and 18 are already marked complete, representing roughly 69% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 19 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University is Pancreatic Cancer with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial